The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Cited by
Sorted by citations
Items 801–900 of 1,005
Prostate Cancer Cells in Different Androgen Receptor Status Employ Different Leucine Transporters
Otsuki, H., Kimura, T., Yamaga, T., Kosaka, T., Suehiro, J., & Sakurai, H. (2016) · The Prostate · doi:10.1002/pros.23263 · Cited by 41
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Rodrigues, D. N., Boysen, G., Sumanasuriya, S., Seed, G., Marzo, A. M. D., & Bono, J. S. D. (2016) · The Journal of Pathology · doi:10.1002/path.4826 · Cited by 41
Exploiting Epigenetic Alterations in Prostate Cancer
Baumgart, S. J., & Haendler, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051017 · Cited by 44
Sharma, N. V., Pellegrini, K. L., Ouellet, V., Giuste, F., Ramalingam, S. S., Watanabe, K. A., Adam-Granger, É., Fossouo, L., You, S., Freeman, M. R., et al. (2018) · Cancers · doi:10.3390/cancers10100379 · Cited by 41
Clinical Applications of Molecular Biomarkers in Prostate Cancer
Couñago, F., López‐Campos, F., Díaz-Gavela, A. A., Almagro, E., Fernández‐Pascual, E., Henriquez, I., Lozano, R., Linares, E., Iturriaga, A. G., de Velasco, G., et al. (2020) · Cancers · doi:10.3390/cancers12061550 · Cited by 42
Melo, C. M., Vidotto, T., Chaves, L. P., Lautert-Dutra, W., dos Reis, R. B., & Squire, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179550 · Cited by 42
RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
Han, W., Liu, M., Han, D. G., Li, M., Toure, A. A., Wang, Z., Besschetnova, A., Patalano, S. C., Macoska, J. A., Gao, S., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02135-3 · Cited by 41
The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer
Xu, P., Wasielewski, L. J., Yang, J. C., Cai, D., Evans, C. P., Murphy, W. J., & Liu, C. (2022) · Biomedicines · doi:10.3390/biomedicines10081778 · Cited by 42
Germline Missense Variants in the BTNL2 Gene Are Associated with Prostate Cancer Susceptibility
FitzGerald, L. M., Kumar, A., Boyle, E. A., Zhang, Y., McIntosh, L. M., Kolb, S., Stott‐Miller, M., Smith, T., Karyadi, D. M., Ostrander, E. A., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0345 · Cited by 41
Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer
Kluth, M., Runte, F., Barow, P., Omari, J., Abdelaziz, Z. M., Paustian, L., Steurer, S. A., Tsourlakis, M. C., Fisch, M., Graefen, M., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29613 · Cited by 40
Kämpjärvi, K., Kim, N. H., Keskitalo, S., Clark, A. D., von Nandelstadh, P., Turunen, M. M., Heikkinen, T., Park, M. J., Mäkinen, N., Kivinummi, K. K., et al. (2015) · The Prostate · doi:10.1002/pros.23092 · Cited by 40
Ci, X., Xing, C., Zhang, B., Zhang, Z., Ni, J. J., Zhou, W., & Dong, J. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0365-6 · Cited by 41
Castro, E., Jugurnauth-Little, S., Karlsson, Q., Al‐Shahrour, F., Piñeiro-Yáñez, E., de Poll, F. V., Leongamornlert, D. A., Dadaev, T., Govindasami, K., Guy, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv356 · Cited by 40
Clonal origin and spread of metastatic prostate cancer
Etten, J. L. V., & Dehm, S. M. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0049 · Cited by 40
Jiang, H., Xiong, W., Chen, L., Lv, Z., Yang, C., & Li, Y. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27851 · Cited by 40
Aggarwal, M., Saxena, R., Asif, N., Sinclair, E., Tan, J., Cruz, I. M., Berry, D. L., Kallakury, B., Pham, Q., Wang, T. T. Y., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1267-z · Cited by 40
Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Mazzu, Y. Z., Armenia, J., Nandakumar, S., Chakraborty, G., Yoshikawa, Y., Jehane, L. E., Lee, G. M., Atiq, M. O., Khan, N. A., Schultz, N. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12706 · Cited by 40
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
Ratta, R., Guida, A., Scotté, F., Neuzillet, Y., Benmaziane, A., Lebrét, T., & Beuzeboc, P. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0233-3 · Cited by 41
Zhang, Y., Cheng, Y., Zhang, Z., Bai, Z.-Y., Jin, H., Guo, X., Huang, X., Li, M., Wang, M., Shu, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00725 · Cited by 40
Yao, M., Shi, X., Li, Y., Xiao, Y., Butler, W., Huang, Y., Du, L., Wu, T., Bian, X., Shi, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02856-5 · Cited by 40
Ma, F., Arai, S., Wang, K., Calagua, C., Yuan, A. R., Poluben, L., Gu, Z., Russo, J. W., Einstein, D. J., Ye, H., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1807 · Cited by 40
Selvaraj, N., Budka, J. A., Ferris, M. W., Jerde, T. J., & Hollenhorst, P. C. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-61 · Cited by 40
Graff, J. N., Puri, S., Bifulco, C. B., Fox, B. A., & Beer, T. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0193 · Cited by 40
Udager, A. M., Shi, Y., Tomlins, S. A., Alva, A. S., Siddiqui, J., Cao, X., Pienta, K. J., Jiang, H., Chinnaiyan, A. M., & Mehra, R. (2014) · The Prostate · doi:10.1002/pros.22836 · Cited by 39
Self-citationEts2 in Tumor Fibroblasts Promotes Angiogenesis in Breast Cancer
Wallace, J. A., Li, F., Balakrishnan, S., Cantemir-Stone, C. Z., Pécot, T., Martin, C. K., Kladney, R. D., Sharma, S. M., Trimboli, A. J., Fernández, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071533 · Cited by 39
High-risk prostate cancer: A disease of genomic instability
Tapia-Laliena, M. Á., Korzeniewski, N., Hohenfellner, M., & Duensing, S. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.02.005 · Cited by 42
Yan, K., You, L., Degerny, C., Ghorbani, M., Liu, X., Chen, L., Li, L., Miao, D., & Yang, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.703041 · Cited by 41
Yoo, S., Choi, S. Y., You, D., & Kim, C. (2016) · Prostate International · doi:10.1016/j.prnil.2016.05.001 · Cited by 40
Zhao, J., Zhao, Y., Wang, L., Zhang, J., Karnes, R. J., Kohli, M., Wang, G., & Huang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9535 · Cited by 41
Páez, A., Pallavicini, C., Schuster, F., Valacco, P., Giudice, J., Ortiz, E. G., Anselmino, N., Labanca, E., Binaghi, M., Salierno, M. J., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.420 · Cited by 39
Yadav, S., Kowolik, C. M., Lin, M., Zuro, D. M., Hui, S. K., Riggs, A. D., & Horne, D. A. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22913 · Cited by 39
Sun, P., Wu, T., Sun, X., Cui, Z., Zhang, H., Xia, Q., & Zhang, D. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108924 · Cited by 39
Larsson, P., Khaja, A. S. S., Semenas, J., Wang, T., Sarwar, M., Dizeyi, N., Simoulis, A., Hedblom, A., Wai, S. N., Ødum, N., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32607 · Cited by 39
Goel, S., Bhatia, V., Kundu, S., Biswas, T., Carskadon, S. L., Gupta, N. S., Asim, M., Morrissey, C. M., Palanisamy, N., & Ateeq, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25623-2 · Cited by 40
Self-citationTranscriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy
Puto, L. A., Brognard, J., & Hunter, T. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.658765 · Cited by 39
Spans, L., den Broeck, T. V., Smeets, E., Preković, S., Thienpont, B., Lambrechts, D., Karnes, R. J., Erho, N., Alshalalfa, M., Davicioni, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8220 · Cited by 39
Should Gleason 6 be labeled as cancer?
Kulaç, İ., Haffner, M. C., Yegnasubramanian, S., Epstein, J. I., & Marzo, A. M. D. (2015) · Current Opinion in Urology · doi:10.1097/mou.0000000000000165 · Cited by 39
Mining Human Prostate Cancer Datasets: The “camcAPP” Shiny App
Dunning, M., Vowler, S. L., Lalonde, E., Ross‐Adams, H., Boutros, P. C., Mills, I. G., Lynch, A. G., & Lamb, A. D. G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.022 · Cited by 39
Fong, K.-W., Zhao, J. C., Lü, X., Kim, J., Piunti, A., Shilatifard, A., & Yu, J. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.11.010 · Cited by 38
A co-clinical platform to accelerate cancer treatment optimization
Lunardi, A., & Pandolfi, P. P. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.008 · Cited by 38
Biomarkers of genome instability and cancer epigenetics
Reis, A. H. O., Vargas, F. R., & Lemos, B. (2016) · Tumor Biology · doi:10.1007/s13277-016-5278-5 · Cited by 40
IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma
Berlow, N., Svalina, M. N., Quist, M. J., Settelmeyer, T. P., Zherebitskiy, V. A., Kogiso, M., Qi, L., Du, Y., Hawkins, C. E., Hulleman, E., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193565 · Cited by 38
Self-citationPEG10 is associated with treatment-induced neuroendocrine prostate cancer
Kim, S., Thaper, D., Bidnur, S., Toren, P., Akamatsu, S., Bishop, J. L., Collins, C. C., Vahid, S., & Zoubeidi, A. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0226 · Cited by 38
Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
Ryan, M. J., & Bose, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01287 · Cited by 40
Dynamics of Cellular Plasticity in Prostate Cancer Progression
Tiwari, R., Manzar, N., & Ateeq, B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00130 · Cited by 40
Self-citationMutant p53 elicits context-dependent pro-tumorigenic phenotypes
McCann, J. J., Vasilevskaya, I. A., McNair, C. M., Gallagher, P., Neupane, N. P., de Leeuw, R., Shafi, A. A., Dylgjeri, E., Mandigo, A. C., Schiewer, M. J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01903-5 · Cited by 40
Wenta, T., Schmidt, A., Zhang, Q., Devarajan, R., Singh, P., Yang, X., Ahtikoski, A. M., Vaarala, M. H., Wei, G., & Manninen, A. (2022) · Oncogene · doi:10.1038/s41388-022-02389-5 · Cited by 38
Sun, X., Fu, X., Li, J., Xing, C., Frierson, H. F., Wu, H., Ding, X., Ju, T., Cummings, R. D., & Dong, J. (2014) · Neoplasia · doi:10.1016/j.neo.2014.05.001 · Cited by 38
Tillman, B. N., Yanik, M., Birkeland, A. C., Liu, C., Hovelson, D. H., Cani, A. K., Palanisamy, N., Carskadon, S. L., Carey, T. E., Bradford, C. R., et al. (2016) · Head & Neck · doi:10.1002/hed.24292 · Cited by 38
Self-citationProstate cancer epigenetics and its clinical implications
Yegnasubramanian, S. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.179859 · Cited by 38
Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside
Sriramulu, S., Thoidingjam, S., Brown, S. L., Siddiqui, F., Movsas, B., & Nyati, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114126 · Cited by 39
Garnham, R., Geh, D., Nelson, R., Ramon‐Gil, E., Wilson, L., Schmidt, E. N., Walker, L., Adamson, B., Buskin, A., Hepburn, A. C., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-05924-0 · Cited by 38
DiPippo, V. A., Olson, W. C., Nguyen, H. M., Brown, L. G., Vessella, R. L., & Corey, E. (2014) · The Prostate · doi:10.1002/pros.22916 · Cited by 37
Examining the impact of gene variants on histone lysine methylation
Rechem, C. V., & Whetstine, J. R. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.05.014 · Cited by 37
Influence of stromal–epithelial interactions on androgen action
Nieto, C., Rider, L. C., & Cramer, S. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0138 · Cited by 40
TMSB4Yis a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer
Wong, H. Y., Wang, G. M., Croessmann, S., Zabransky, D. J., Chu, D. T. W., Garay, J. P., Cidado, J. R., Cochran, R. L., Beaver, J. A., Aggarwal, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6743 · Cited by 37
Ecotropic viral integration site 1, a novel oncogene in prostate cancer
Queisser, A., Hagedorn, S., Wang, H., Schaefer, T., Konantz, M., Alavi, S., Deng, M., Vogel, W., von Mäßenhausen, A., Kristiansen, G., et al. (2016) · Oncogene · doi:10.1038/onc.2016.325 · Cited by 37
Malek, R. A., Wang, H., Taparra, K., & Tran, P. T. (2017) · Cells Tissues Organs · doi:10.1159/000447238 · Cited by 40
Targeting Lyn regulates Snail family shuttling and inhibits metastasis
Thaper, D., Vahid, S., Nip, K. M., Moskalev, I., Shan, X., Frees, S., Roberts, M. E., Ketola, K., Harder, K. W., Gregory, C. Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.5 · Cited by 37
Wang, Y., Wang, J., Zhang, L., Karataş, Ö. F., Shao, L., Zhang, Y., Castro, P. D., Creighton, C. J., & Ittmann, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0669 · Cited by 37
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
Singhal, U., Wang, Y., Henderson, J., Niknafs, Y. S., Qiao, Y., Gursky, A. M., Zaslavsky, A., Chung, J., Smith, D. C., Karnes, R. J., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0539 · Cited by 37
Self-citationCriscuolo, D., Morra, F., Giannella, R., Cerrato, A., & Celetti, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123100 · Cited by 40
Fu, C., An, N., Liu, J., Jun, A., Zhang, B., Liu, M., Zhang, Z., Fu, L., Tian, X., Wang, D., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012131 · Cited by 37
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA
Wu, Y., Xie, J., Jin, X., Lenchine, R. V., Wang, X., Fang, D. M., Nassar, Z. D., Butler, L. M., Li, J., & Proud, C. G. (2020) · Biochemical Journal · doi:10.1042/bcj20200697 · Cited by 37
Self-citationMitsiades, N., & Kaochar, S. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0098 · Cited by 39
Ebersbach, C., Beier, A.-M. K., Thomas, C., & Erb, H. H. H. (2021) · Cancers · doi:10.3390/cancers13194854 · Cited by 38
Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression
Linn, D. E., Penney, K. L., Bronson, R. T., Mucci, L. A., & Li, Z. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1911 · Cited by 37
The role of CREB3L4 in the proliferation of prostate cancer cells
Kim, T. H., Park, J.-M., Kim, M., & Ahn, Y. (2017) · Scientific Reports · doi:10.1038/srep45300 · Cited by 41
Yamamoto, S., Takayama, K., Obinata, D., Fujiwara, K., Ashikari, D., Takahashi, S., & Inoue, S. (2019) · Cancer Science · doi:10.1111/cas.14183 · Cited by 37
Prostate OrganogenesisPreprint
Francis, J. C., & Swain, A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030353 · Cited by 37
ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells
Mochmann, L. H., Neumann, M., von der Heide, E. K., Nowak, V., Kühl, A. A., Ortiz-Tánchez, J., Bock, J., Hofmann, W. K., & Baldus, C. D. (2013) · Oncotarget · doi:10.18632/oncotarget.1449 · Cited by 36
Role of lncRNAs in prostate cancer development and progression
Weiß, M., Plass, C., & Gerhäuser, C. (2014) · Biological Chemistry · doi:10.1515/hsz-2014-0201 · Cited by 36
Qiu, X., Zhu, J., Sun, Y., Fan, K., Yang, D., Li, G., Yang, G., & Chang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3778 · Cited by 36
Wang, J., Li, Z., Lin, Z., Zhao, B., Wang, Y., Peng, R., Wang, M., Lu, C., Shi, G., & Shen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.025 · Cited by 38
Kohli, M., Wang, L., Xie, F., Sicotte, H., Yin, P., Dehm, S. M., Hart, S. N., Vedell, P. T., Barman, P., Qin, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145176 · Cited by 36
The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer
Yoo, Y. A., Vatapalli, R. J., Lysy, B., Mok, H., Desouki, M. M., & Abdulkadir, S. A. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy142 · Cited by 37
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 37
Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
Verma, S., Prajapati, K. S., Kushwaha, P. P., Shuaib, M., Singh, A. K., Kumar, S., & Gupta, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.45 · Cited by 37
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression
Shang, W., Wang, Y., Liang, X., Li, T., Shao, W., Liu, F., Cui, X., Wang, Y., Lv, L., Chai, L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5568 · Cited by 37
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
Chen, X., Ma, Q., Shang, Z., & Niu, Y. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00137-0 · Cited by 37
Shi, L., Yan, Y., He, Y., Yan, B., Pan, Y., Orme, J. J., Zhang, J., Xu, W., Pang, J., & Huang, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3258 · Cited by 36
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients
Balázs, K., Antal, L., Sáfrány, G., & Lumniczky, K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040296 · Cited by 37
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
Tomlins, S. A., Hovelson, D. H., Suga, J. M., Anderson, D. M., Koh, H. A., Dees, E. C., McNulty, B., Burkard, M. E., Guarino, M. J., Khatri, J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00472 · Cited by 36
Self-citationTHEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer
Blomme, A., Peter, C., Mui, E., Rodriguez Blanco, G., An, N., Mason, L. M., Jamieson, L. E., McGregor, G. H., Lilla, S., Ntala, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114764 · Cited by 36
Race and prostate cancer: genomic landscape
Gallo, C. A., Owiredu, J. N., Weinstein, I., Lewicki, P., Basourakos, S. P., Vince, R., Awamlh, B. A. H. A., Schumacher, F. R., Spratt, D. E., Barbieri, C. E., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00622-0 · Cited by 36
Huang, J.-L., Yan, X., Li, W., Fan, R., Li, S., Chen, J., Zhang, Z., Sang, J., Gan, L., Tang, G., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c06449 · Cited by 39
Fan, L., Peng, G., Hussain, A., Fazli, L., Guns, E. S. T., Gleave, M. E., & Qi, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.662155 · Cited by 36
Rodriguez, M., Siwko, S. K., Zeng, L., Li, J., Yi, Z., & Liu, M. (2015) · Oncogene · doi:10.1038/onc.2015.170 · Cited by 36
Cancer in the parasitic protozoans Trypanosoma brucei and Toxoplasma gondii
Lun, Z., Lai, D., Wen, Y., Zheng, L., Shen, J.-L., Yang, T.-B., Zhou, W., Qu, L., Hide, G., & Ayala, F. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502599112 · Cited by 39
Destruction of DDIT3/CHOP Protein by Wild-Type SPOP but Not Prostate Cancer-Associated Mutants
Zhang, P., Gao, K., Tang, Y., Jin, X., An, J., Yu, H., Wang, H., Zhang, Y., Wang, D., Huang, H., et al. (2014) · Human Mutation · doi:10.1002/humu.22614 · Cited by 36
Mutation Spectra of Histone Methyltransferases With Canonical SET Domains and EZH2-Targeted Therapy
Katoh, M. (2015) · Epigenomics · doi:10.2217/epi.15.89 · Cited by 36
Kashyap, V., & Bonavida, B. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.12 · Cited by 36
BAP18 coactivates androgen receptor action and promotes prostate cancer progression
Sun, S., Zhong, X., Wang, C., Sun, H., Wang, S., Zhou, T., Zou, R., Lin, L., Sun, N., Sun, G., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw472 · Cited by 36
Self-citationMolecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis
Corcoran, N. M., Clarkson, M. J., Stuchbery, R., & Hovens, C. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1050 · Cited by 37
Decoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 35
A global profile of gene promoter methylation in treatment-naïve urothelial cancer
Ibragimova, I., Dulaimi, E., Slifker, M. J., Chen, D. D., Uzzo, R. G., & Cairns, P. (2014) · Epigenetics · doi:10.4161/epi.28078 · Cited by 35
Tumor suppressor RARRES1- A novel regulator of fatty acid metabolism in epithelial cells
Maimouni, S., Issa, N. T., Cheng, S., Ouaari, C., Cheema, A. K., Kumar, D., & Byers, S. W. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208756 · Cited by 35
Velasco, M. A. D., Kura, Y., Sakai, K., Hatanaka, Y., Davies, B. R., Campbell, H., Klein, S., Kim, Y. S., MacLeod, A. R., Sugimoto, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122688 · Cited by 37
NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis
Saga, K., Park, J., Nimura, K., Kawamura, N., Ishibashi, A., Nonomura, N., & Kaneda, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1429-z · Cited by 35
Optimizing the diagnosis and management of ductal prostate cancer
Ranasinghe, W. K. B., Shapiro, D. D., Zhang, M., Bathala, T. K., Navone, N. M., Thompson, T. C., Broom, B. M., Aparicio, A. M., Tu, S., Tang, C. Z., et al. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00447-3 · Cited by 36
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
